Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 10 2022 - 5:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 9, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk
shares by board members, executives and associated persons on 4 February 2022
Bagsværd,
Denmark, 9 February 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares
by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014
on market abuse.
The company’s board members, executives and their
associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s
board members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
Page 2 of 6
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name of the Board member/Executive/Associated Person
|
Doug Langa
|
|
2
|
Reason for the notification
|
|
|
a)
|
Position/status
|
Executive vice president, North America Operations
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer
|
|
|
a)
|
Name
|
Novo Nordisk A/S
|
|
b)
|
LEI
|
549300DAQ1CVT6CXN342
|
|
4
|
Details of the transaction(s)
|
|
|
a)
|
Description of the financial instrument, type of instrument,
|
ADRs
|
|
|
Identification code
|
NVO
|
|
b)
|
Nature of the transaction
|
Purchase of ADRs
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
DKK 647.41
|
1,931.7 ADRs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
· Aggregated volume
|
1,931.7 ADRs
|
|
|
· Price
|
DKK 647.41
|
|
e)
|
Date of the transaction
|
2022-02-04
|
|
f)
|
Place of the transaction
|
New York Stock Exchange
|
|
Page 3 of 6
1
|
Details of the person discharging managerial responsibilities/person closely
|
|
|
|
associated
|
|
|
a)
|
Name of the Board member/Executive/Associated
Person
|
Doug Langa
|
|
2
|
Reason for the notification
|
|
|
a)
|
Position/status
|
Executive vice president, North America Operations
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer
|
|
|
a)
|
Name
|
Novo Nordisk A/S
|
|
b)
|
LEI
|
549300DAQ1CVT6CXN342
|
|
4
|
Details of the transaction(s)
|
|
|
a)
|
Description of the financial instrument, type of instrument,
|
ADRs
|
|
|
Identification code
|
NVO
|
|
b)
|
Nature of the transaction
|
Sale of ADRs
|
|
c)
|
Price(s)
and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
DKK 647.24
|
22.3 ADRs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
·
Aggregated volume
|
22.3 ADRs
|
|
|
·
Price
|
DKK 647.24
|
|
e)
|
Date of the transaction
|
2022-02-04
|
|
f)
|
Place of the transaction
|
New York Stock Exchange
|
|
Page 4 of 6
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
|
a)
|
Name of the Board member/Executive/Associated Person
|
Doug Langa
|
|
2
|
Reason for the notification
|
|
|
a)
|
Position/status
|
Executive vice president, North America Operations
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer
|
|
|
a)
|
Name
|
Novo Nordisk A/S
|
|
b)
|
LEI
|
549300DAQ1CVT6CXN342
|
|
4
|
Details of the transaction(s)
|
|
|
a)
|
Description of the financial instrument, type of instrument,
|
ADRs
|
|
|
Identification code
|
NVO
|
|
b)
|
Nature of the transaction
|
Purchase of ADRs
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
DKK 647.59
|
510.4 ADRs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
· Aggregated volume
|
510.4 ADRs
|
|
|
· Price
|
DKK 647.59
|
|
e)
|
Date of the transaction
|
2022-02-04
|
|
f)
|
Place of the transaction
|
New York Stock Exchange
|
|
Page 5 of 6
Definitions and background information:
Publication
Publication shall take place no later than three working
days after the trading by board members, executives or their associated persons. Publication is only required when the total amount of
transactions of a specific board member/executive or his/her associated persons in any one calendar year has reached EUR 20,000 (calculated
individually).
Who are board members, executives and associated persons?
Board members and executives are members of the Board
of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated
to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other relatives defined as brothers, sisters,
parents, grandparents, children, grandchildren, cousins etc. who have shared the same household with a board member or executive for a
period of at least one year on the date of the given transaction and 4) any legal persons, trust, or partnership, the managerial responsibilities
of which are discharged by a board member/executive or by a person referred to in items 1)-3) above, or which is directly or indirectly
controlled by such a person, or which is set up for the benefit of such a person, or the economic interests of which are substantially
equivalent to those of such a person.
What is trading/transaction?
Trading is any kind of transaction, including shares
and share related securities purchased or otherwise acquired, sold or otherwise disposed, gifts, mortgages, heritage and grants, allotments
and exercise of options.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq
Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code
is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.
What is date and place of transaction?
Date of transaction is the
actual transaction date. The place of transaction is the actual place of transaction, i.e. Nasdaq Copenhagen or New York Stock
Exchange.
What is the volume and price of transaction and aggregated
information?
The volume of transaction is the number of shares (of DKK
0.20 nominal value) or other financial instruments traded. In case of a single transaction the price is the price of that single transaction.
In case of multiple transactions, when the transactions relate to the same financial instrument, are of the same nature, are executed
on the same day and are executed on the same place, the volume must be aggregated. The price of the aggregated transactions is the weighted
average price.
The exchange rate of the Danish Central Bank (Nationalbanken)
on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.
Page 6 of 6
Novo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other
serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding
access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries
and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed
on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 4442 3883
|
mkd@novonordisk.com
|
Michael Bachner (US)
|
+1 609 664 7308
|
mzyb@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
David Heiberg Landsted
|
+45 3077 6915
|
dhel@novonordisk.com
|
Jacob Martin Wiborg Rode
|
+45 3075 5956
|
jrde@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 10 / 2022
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 9, 2022
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024